Amy Yu

Amy has extensive experience in advising financial institutions, private clients and listed companies and conglomerates on their corporate transactions, including mergers and acquisitions, joint ventures, corporate reorganizations, and investment agreements. She also frequently advises listed companies on compliance with the Hong Kong Listing Rules and securities laws. She is therefore well-positioned to satisfy both transactional and compliance needs of listed companies.

In addition, Amy has throughout a large portion of her career, advised issuers, sponsors and underwriters on the listing of companies on the Hong Kong Stock Exchange. She advised companies operating in a wide range of sectors, including life science, food and beverage manufacturers and retailers, real estate developers, financial institutions, industrial manufacturers and more. Her can-do attitude and attentiveness to client needs have made her a trusted adviser to many clients.

Amy's life sciences experience includes:

• Advising AOBiome Therapeutics, Inc., on its proposed Chapter 18A listing on HKEX which is sponsored by Citi and Haitong International.  AOBiome is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systematic diseases.
• Advising China International Capital Corporation Hong Kong Securities Limited (CICC) as sole sponsor and sole global coordinator in connected with the Chapter 18A listing of Mabpharm Limited, a biotech company, on the Main Board of HKEX raising approximately HK$1.2 billion.